| abstract |
The present invention relates to a pharmaceutical formulation comprising about 50 mg/ml – 200 mg/ml of an Abeta antibody, about 0.01 % – 0.1% poloxamer, about 5 mM – 50 mM of a buffer, about 100 m M – 300 m M of a stabilizer at a pH of about 4.5 – 7.0. |